14 March 2024
Scancell Holdings plc
("Scancell" or the "Company")
Appointment of Sath Nirmalananthan to the Board of Directors
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that Sath Nirmalananthan, Chief Financial Officer, has been appointed to the Company's Board of Directors (the "Board") with immediate effect.
Sath was appointed as the Company's Chief Financial Officer on 29 August 2023, having previously served as Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. He brings more than 15 years' experience in the healthcare sector, and has held roles at FTSE and NASDAQ listed companies, including Reckitt and BTG. Prior to this Sath held positions in investment banking at Nomura, and at KPMG. Sath is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales (ICAEW), and sits as a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR). He was awarded a BSc in Pharmacology from King's College, London.
Dr Jean-Michel Cosséry, Non-Executive Chairman of Scancell, commented: "Since joining Scancell in August last year, Sath has brought considerable experience and expertise to the role, overseeing our successful £12 million fundraise from new and existing investors. Our focus remains on progressing SCIB1 and Modi-1 through the clinic whilst also actively seeking out-licensing, collaborations, and partnerships to accelerate the development and commercialisation of our products and platforms. Working closely with the Board, and Executive team, Sath will be instrumental in driving us towards realising the potential of these treatments for patients, while creating and delivering significant long-term value for our shareholders."
Commenting on his new appointment, Sath Nirmalananthan, Chief Financial Officer and Director of Scancell, said: "I am proud to take on this expanded role as a member of the Board, and I look forward to working with my fellow Board members and the wider team to deliver our goals for 2024 and beyond. This is an exciting time to be part of Scancell, as we continue to build significant momentum and approach a number of important clinical milestones, anticipated later this year, including further data from both the SCOPE and ModiFY trials."
Additional Information
In accordance with the AIM Rules, the following information required to be disclosed in relation to Sath Nirmalananthan is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.
Full name and age: Sathijeevan Nirmalananthan, aged 38
| |
|
| Current Directorships | Previous Directorships (last 5 years) |
| PNSN Company Limited | Oxsed Limited |
| | DNA Fit Limited |
| | DNA Sport Limited |
| | DNAFIT Life Sciences Limited |
| | Prenetics EMEA Limited |
| | Prenetics Consumer Healthcare Limited |
| | Duo Doc Limited |
| | Norse Medica Limited |
| | SP Care Holdings Limited |
Mr Sath Nirmalananthan does not have an interest in any ordinary shares or share options in Scancell.
| For further information, please contact: | |
| | |
| Scancell Holdings plc | +44 (0) 20 3709 5700 |
| Dr Jean-Michel Cosséry, Non-Executive Chairman | |
| Professor Lindy Durrant, CEO | |
| | |
| Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7710 7600 |
| Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking) | |
| Nick Adams/Nick Harland (Corporate Broking)
| |
| WG Partners LLP (Joint Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby
| +44 (0) 20 3705 9330
|
| Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
| Freddy Crossley/Emma Earl (Corporate Finance) | |
| Rupert Dearden (Corporate Broking) | |
| | |
| ICR Consilium | +44 (0) 20 3709 5700 |
| Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.